Brentuximab vedotin
- Generic Name
- Brentuximab vedotin
- Brand Names
- Adcetris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914088-09-8
- Unique Ingredient Identifier
- 7XL5ISS668
- Background
Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...
- Indication
Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...
- Associated Conditions
- CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
- Associated Therapies
- -
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT01060904
- Locations
- 🇺🇸
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT01026415
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
🇺🇸St. Francis Medical Group Oncology & Hematology Specialists, Indianapolis, Indiana, United States
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
- Conditions
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01026233
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
- Conditions
- Interventions
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00947856
- Locations
- 🇺🇸
Loyola University Medical Center - Cardinal Bernadin Cancer Center, Maywood, Illinois, United States
🇺🇸The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT00866047
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT00848926
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
🇫🇷Institut Paoli Calmettes, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.